Navigation Links
Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection

ries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of RPLS in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
2. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
3. Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments
4. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
5. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
8. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
9. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
10. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
11. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
Post Your Comments:
(Date:7/30/2014)... , July 30, 2014 Reportlinker.com announces ... in its catalogue: mHealth and Home ... http://www.reportlinker.com/p0356852/mHealth-and-Home-Monitoring-–-6th-Edition.html Executive summary ... leading to better outcomes, decreased costs and improved ... mHealth solutions is still in an early stage, ...
(Date:7/30/2014)... , July 30, 2014   Unique Pizza ... Inc.: OTC Pink: UPZS), a Delaware Corporation, is ... agreement with Larasan Pharmaceutical Corporation ("Larasan"), a nature-based pharmaceutical ... to the agreement, US-based Larasan will work with ... frozen pizza through Larasan,s vast distribution network throughout ...
(Date:7/30/2014)... Cynosure, Inc. (NASDAQ: CYNO ... non-invasive and minimally invasive applications, today announced that the Board ... and Chief Financial Officer Timothy W. Baker to ... will continue to serve as CFO and will take the ... Chairman and Chief Executive Officer. "Tim has ...
Breaking Medicine Technology:mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
... July 13, 2011 The U.S. Food and Drug ... care providers and patients that surgical placement of mesh ... expose patients to greater risk than other surgical options. ... The safety communication also says that with the exposure ...
... 2011 When flu season arrives this fall, a ... medication—will be available in a new, lower concentration to ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The change applies ... is a powder form of the prescription medication that ...
Cached Medicine Technology:FDA: Surgical Placement of Mesh to Repair Pelvic Organ Prolapse Poses Risks 2FDA: Surgical Placement of Mesh to Repair Pelvic Organ Prolapse Poses Risks 3FDA: Surgical Placement of Mesh to Repair Pelvic Organ Prolapse Poses Risks 4FDA CONSUMER HEALTH INFORMATION - Concentration Lowered in Tamiflu Medication 2
(Date:7/30/2014)... Steven Reinberg HealthDay Reporter ... the United States, at least 2,000 Americans die from extreme ... Heat waves, heat stroke or sun stroke caused nearly ... and 2010, according to the U.S. Centers for Disease Control ... loss of body heat -- accounted for 63 percent of ...
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... July 30, 2014 Visitors to our ... over $8,500 to ensure its protection. Bob Kiesendahl, one ... check to the Delaware Highlands Conservancy for donations collected ... small $2-per-stay donations add up fast, as visitors welcome ... Upper Delaware River Region. , The Kiesendahl family has ...
(Date:7/30/2014)... KY (PRWEB) July 30, 2014 DRE ... pleased to announce the launch of its Medical ... online resource for medical professionals and equipment vendors. , ... shows and conventions in the United States and around ... the calendar, and that number is always growing. , ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased to ... will serve as chair. The board was voted upon ... Conference in Houston, Texas July 10-12. , “The ... us. From the rollout of the first EDNF Center ... Medical Center to our September physicians conference to a ...
Breaking Medicine News(10 mins):Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Ehlers-Danlos National Foundation Announces New Leadership 2
... 05, 2008 A new study published in Journal ... sclerosis (MS) patients to determine if the disease has affected ... progression of disability. , MS affects approximately 400,000 people in ... It is the most common cause of progressive disability in ...
... Professionals to Maintain Licensing or Certification, WASHINGTON, ... for completing an American Red Cross,First Aid/CPR Class ... happen., Red Cross has been approved as ... Association for Continuing Education and,Training (IACET). The approval ...
... survey shows people living with epilepsy often miss ... continues to build on the company,s commitment to ... XR(TM) (levetiracetam),extended-release tablets, -- Keppra XR(TM) is ... Epilepsy,Franchise, ATLANTA, Nov. 5 press release, ...
... havens for healing, but the numbers tell a different ... acquire after they,ve been admitted, and hospital-related infections continue ... heart disease. , Now, a radical new high-tech software ... these infections is now catching on faster than the ...
... for Medical Equipment, Facility,Design, Building Infrastructure and ... and NEW YORK, Nov. 5 Cirrus ... to provide a wide,range of technology and ... healthcare environments., (Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ...
... Use Tobacco Settlement Money to Keep Kids from ... Executive Director, Campaign for,Tobacco-Free Kids, WASHINGTON, Nov. ... victory for the state,s kids and health by ... reduce smoking, save lives,and lower health care costs ...
Cached Medicine News:Health News:Multiple sclerosis progression can be predicted with MRI 2Health News:American Red Cross Offering Continuing Education Credits 2Health News:Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures 2Health News:Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures 3Health News:Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures 4Health News:Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures 5Health News:Reducing epic proportions 2Health News:Cirrus Health and Siemens Announce Technology Alliance to Deliver the Physician-Driven Hospital of the Future 2Health News:Cirrus Health and Siemens Announce Technology Alliance to Deliver the Physician-Driven Hospital of the Future 3Health News:North Dakota Votes to Keep Promise to Kids by Fully Funding Tobacco Prevention 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: